Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Medical Ultrasonics
Published in: Journal of Medical Ultrasonics 2/2015

01-04-2015 | Case Report

Neuroendocrine tumor of gallbladder with liver and retroperitoneal metastases and a good response to the chemotherapeutical treatment

Authors: Liliana Chiorean, Adrian Bartos, Doris Pelau, Dana Iancu, Tudor Ciuleanu, Rares Buiga, Irinel Oancea, Angelica Mangrau, Cornel Iancu, Radu Badea

Published in: Journal of Medical Ultrasonics | Issue 2/2015

Login to get access

Abstract

Neuroendocrine carcinoma of the gallbladder is an uncommon disease. We present the case of a 45-year-old woman with a mass located in the gallbladder, whose diagnosis was based on contrast-enhanced ultrasound and magnetic resonance imaging. The tumor involved the liver and retroperitoneum, and was histopathologically confirmed by liver biopsy as a neuroendocrine tumor grade 3. The patient received chemotherapy with good response, followed by surgery with cholecystectomy and partial hepatectomy.
Literature
1.
Lawrence B, Gustafsson BI, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40:1–18.CrossRefPubMed
2.
Frilling A, Modlin IM, Kidd M, et al. for the Working Group on Neuroendocrine Liver Metastases. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 2014;15:e8–21. www.​thelancet.​com/​oncology.
3.
John BJ, Davidson BR. Treatment options for unresectable neuroendocrine liver metastases. Expert Rev Gastroenterol Hepatol. 2012;6:357–69.CrossRefPubMed
4.
Albores-Saavedra J, Henson DE. Tumors of the Gallbladder and Extrahepatic Bile ducts. Radiographics. 2002;22:387–413.CrossRef
5.
Hamilton SR, Aaktonen LA. Pathology and genetics, tumors of the digestive system. WHO. 2000;214–6.
6.
Jamali M, Chetty R. Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining. Endocr Pathol. 2008;19:282–8.CrossRefPubMed
7.
Dhall D, Mertens R, Bresee C, et al. Ki-67 proliferative index predicts progression-free survival of patients with well differentiated ileal neuroendocrine tumors. Hum Pathol. 2012;43:489–95.CrossRefPubMed
8.
Eltawil KM, Gustafsson BI, Kidd M, et al. Neuroendocrine tumors of the gallbladder: an evaluation and reassessment of management strategy. J Clin Gastroenterol. 2010;44:687–95.PubMed
9.
Iwao M, Nakamura M, Enjoji M, et al. Primary hepatic carcinoid tumor: case report and review of 53 cases. Med Sci Monit. 2001;7:746–50.PubMed
10.
Albores-Saavedra J, Molberg K, Henson DE. Unusual malignant epithelial tumors of the gallbladder. Semin Diagn Pathol. 1996;13:326–38.PubMed
11.
Maitra A, Tascilar M, Hruban RH, et al. Small cell carcinoma of the gallbladder. A clinicopathologic, immunohistochemical, and molecular pathology study of 12 cases. Am J Surg Pathol. 2001;25:595–601.CrossRefPubMed
12.
Yamamoto M, Nakajo S, Miyoshi N, et al. Endocrine cell carcinoma (Carcinoid) of the gallbladder. Am J Surg Pathol. 1989;13:292–302.CrossRefPubMed
13.
Bosl GJ, Yagoda A, Camara LL. Malignant carcinoid of the gallbladder: third reported case and review of the literature. J Surg Oncol. 1980;13:215–22.CrossRefPubMed
14.
Komminoth P, Arnold R, Capella C, et al. Neuroendocrine neoplasms of the gallbladder and extrahepatic bile ducts. In: Bosman FT, Carneiro F, Hruban RH, et al., editors. WHO Classification of Tumours of the Digestive System. Lyon: IARC Press; 2010. p. 274–6.
15.
Lepage C, Ciccolallo L, De Angelis R, et al. European disparities in malignant digestive endocrine tumours survival. Int J Cancer. 2010;126:2928–34.PubMed
16.
Albores-Saavedra J, Nadji M, Henson DE, et al. Intestinal metaplasia of the gallbladder: a morphologic and immunocytochemical study. Hum Pathol. 1986;17:614–20.CrossRefPubMed
17.
Papotti M, Cassoni P, Sapino A, et al. Large cell neuroendocrine carcinoma of the gallbladder: report of two cases. Am J Surg Pathol. 2000;24:1424–8.CrossRefPubMed
18.
Wakiyama S, Yoshimura K, Shimada M, et al. Heterotopic gastric mucosa in a gallbladder with an anomalous union of the pancreatobiliary duct: a case report. Hepatogastroenterology. 1998;45:1488–91.PubMed
19.
Modlin IM, Lye KD, Kidd M. A 5-Decade Analysis of 13,715 Carcinoid Tumors. Cancer. 2003;97:934–59.CrossRefPubMed
20.
McDermott EW, Guduric B, Brennan MF. Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg. 1994;81:1007–9.CrossRefPubMed
21.
Rindi G, D’Adda T, Froio E, et al. Prognostic factors in gastrointestinal endocrine tumors. Endocr Pathol. 2007;18:145–9.CrossRefPubMed
22.
Jung EM, Ross CJ, Rennert J, et al. Characterization of microvascularization of liver tumor lesions with high resolution linear ultrasound and contrast enhanced ultrasound (CEUS) during surgery: first results. Clin Hemorheol Microcirc. 2010;46:89–99.PubMed
23.
Rickes S, Ocran KW, Gerstenhauer G, et al. Evaluation of diagnostic criteria for liver metastases of adenocarcinomas and neuroendocrine tumours at conventional ultrasound, unenhanced power Doppler sonography and echoenhanced ultrasound. Dig Dis. 2004;22:81–6.CrossRefPubMed
24.
d’Assignies G, Fina P, Bruno O, et al. High sensitivity of diffusion weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging. Radiology. 2013; 268:390–99.
25.
Frilling A, Sotiropoulos GC, Radtke A, et al. The impact of 68 Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg. 2010;252:850–6.CrossRefPubMed
26.
Ruf J, Heuck F, Schiefer J, et al. Impact of multiphase 68 Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology. 2010;91:101–9.CrossRefPubMed
27.
Elias D, Lefevre JH, Duvillard P, et al. Hepatic metastases from neuroendocrine tumors with a “thin slice” pathological examination: they are many more than you think. Ann Surg. 2010;251:307–10.CrossRefPubMed
28.
Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999;86:858–65.CrossRefPubMed
29.
Seregni E, Ferrari L, Bajetta E, et al. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol. 2001;12:S69–72.CrossRefPubMed
30.
Soga J. Primary endocrinomas (carcinoid and variant neoplasm) of the gallbladder. A Statistical evaluation of 138 reported cases. J Exp Clin Cancer Res. 2001;22:5–15.
31.
Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157–76.CrossRefPubMed
32.
Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29–37.CrossRefPubMed
33.
Elias D, Lasser P, Ducreux M, et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery. 2003;133:375–82.CrossRefPubMed
34.
Glazer ES, Tseng JF, Al-Refaie W, et al. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford). 2010;12:427–33.CrossRefPubMedCentralPubMed
35.
Iype S, Mirza TA, Propper DJ. Neuroendocrine tumours of the gallbladder: three cases and a review of the literature. Postgrad Med J. 2009;85:213–8.CrossRefPubMed
36.
Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999;81:1351–5.CrossRefPubMedCentralPubMed
37.
Moertel CG, Kvols LK, O’Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68:227–32.CrossRefPubMed
38.
39.
Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61–72.CrossRefPubMed
Metadata
Title
Neuroendocrine tumor of gallbladder with liver and retroperitoneal metastases and a good response to the chemotherapeutical treatment
Authors
Liliana Chiorean
Adrian Bartos
Doris Pelau
Dana Iancu
Tudor Ciuleanu
Rares Buiga
Irinel Oancea
Angelica Mangrau
Cornel Iancu
Radu Badea
Publication date
01-04-2015
Publisher
Springer Japan
Published in
Journal of Medical Ultrasonics / Issue 2/2015
Print ISSN: 1346-4523
Electronic ISSN: 1613-2254
DOI
https://doi.org/10.1007/s10396-014-0585-1

Other articles of this Issue 2/2015

Journal of Medical Ultrasonics 2/2015 Go to the issue

Review Article

Evolution of pancreas in aging: degenerative variation or early changes of disease?

Original Article

How do the trends in the prenatal diagnosis of aneuploidy change after a non-invasive prenatal test becomes available? A Japanese single center study

Editorial

The pediatric gastrointestinal tract and ultrasonography

Ultrasound Image of the Month

Importance of ultrasound in work-up of a cystic neck mass

Original Article

Contrast-enhanced ultrasound for evaluation of renal trauma during acute hemorrhagic shock: a canine model

Original Article

Effects of gradual low-flow reperfusion postconditioning on ischemia–reperfusion injury involving incomplete testicular torsion in rabbits